Skip to main content
. Author manuscript; available in PMC: 2013 Aug 14.
Published in final edited form as: Hypertension. 2012 Sep 4;60(4):981–990. doi: 10.1161/HYPERTENSIONAHA.112.201509

Figure 11. Chronic treatment of PI3K inhibitor (NVP-BEZ235) suppressed increased NCC phosphorylation and blood pressure in db/db mice.

Figure 11

A. Representative immunoblots of phosphorylation of OSR1/SPAK and NCC from db/db and control mouse kidney, with or without administration of a PI3K inhibitor (NVP-BEZ235).

B. Densitometry analysis; NVP-BEZ235 suppressed increased OSR1/SPAK and NCC phosphorylation in db/db mouse kidney. Mean ± SEM. (n=4). *p<0.05, **p<0.01.

C. Systolic blood pressure is decreased only in db/db mice with NVP-BEZ235, compared to vehicle treated db/db mice. Mean ± SEM. (n as indicated). *p<0.05.